Cladribine Tablets is an experimental treatment that has been studied in relapsing forms of multiple sclerosis.  The FDA has granted a priority review which means a decision for FDA approval could occur with 6 months.  EMD Serono announced that a decision on this oral therapy is expected in the last quarter of the year in 2010.

Posted by Barry Singer, MD on July 28th, filed under MS Research News.